-
1
-
-
0026487210
-
Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors
-
Houghton PJ, Chesire PJ, Myers L, Stewart CF, Synold TW, Houghton JA. Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors. Cancer Chemother Pharmacol 1992;31:229-39.
-
(1992)
Cancer Chemother Pharmacol
, vol.31
, pp. 229-239
-
-
Houghton, P.J.1
Chesire, P.J.2
Myers, L.3
Stewart, C.F.4
Synold, T.W.5
Houghton, J.A.6
-
2
-
-
0029116438
-
Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors
-
Houghton PJ, Cheshire PJ, Hallman JD, et al. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 1995;36:393-403.
-
(1995)
Cancer Chemother Pharmacol
, vol.36
, pp. 393-403
-
-
Houghton, P.J.1
Cheshire, P.J.2
Hallman, J.D.3
-
3
-
-
0037087762
-
Protracted intermittent schedule of topotecan in children with refractory acute leukemia: A Pediatric Oncology Group study
-
Furman WL, Stewart CF, Kirstein M, et al. Protracted intermittent schedule of topotecan in children with refractory acute leukemia: a Pediatric Oncology Group study. J Clin Oncol 2002;20:1617-24.
-
(2002)
J Clin Oncol
, vol.20
, pp. 1617-1624
-
-
Furman, W.L.1
Stewart, C.F.2
Kirstein, M.3
-
4
-
-
0028357993
-
Phase I study of topotecan for pediatric patients with malignant solid tumors
-
Pratt CB, Stewart CF, Santana VM, et al. Phase I study of topotecan for pediatric patients with malignant solid tumors. J Clin Oncol 1994;12:539-43.
-
(1994)
J Clin Oncol
, vol.12
, pp. 539-543
-
-
Pratt, C.B.1
Stewart, C.F.2
Santana, V.M.3
-
5
-
-
0037316914
-
A pilot study of protracted topotecan dosing using a pharmacokinetically guided dosing approach in children with solid tumors
-
Santana VM, Zamboni WC, Kirstein MN, et al. A pilot study of protracted topotecan dosing using a pharmacokinetically guided dosing approach in children with solid tumors. Clin Cancer Res 2003;9:633-40.
-
(2003)
Clin Cancer Res
, vol.9
, pp. 633-640
-
-
Santana, V.M.1
Zamboni, W.C.2
Kirstein, M.N.3
-
6
-
-
4344566362
-
Results of a phase II upfront window of pharmacokinetically guided topotecan in high-risk medulloblastoma and supratentorial primitive neuroectodermal tumor
-
Stewart CF, Iacono LC, Chintagumpala M, et al. Results of a phase II upfront window of pharmacokinetically guided topotecan in high-risk medulloblastoma and supratentorial primitive neuroectodermal tumor. J Clin Oncol 2004;22:3357-65.
-
(2004)
J Clin Oncol
, vol.22
, pp. 3357-3365
-
-
Stewart, C.F.1
Iacono, L.C.2
Chintagumpala, M.3
-
7
-
-
0036140067
-
Phase I study of combination topotecan and carboplatin in pediatric solid tumors
-
Athale UH, Stewart C, Kuttesch JF, et al. Phase I study of combination topotecan and carboplatin in pediatric solid tumors. J Clin Oncol 2002;20:88-95.
-
(2002)
J Clin Oncol
, vol.20
, pp. 88-95
-
-
Athale, U.H.1
Stewart, C.2
Kuttesch, J.F.3
-
8
-
-
0035424844
-
Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: A Pediatric Oncology Group phase II study
-
Saylors RL, III, Stine KC, Sullivan J, et al. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. J Clin Oncol 2001;19:3463-9.
-
(2001)
J Clin Oncol
, vol.19
, pp. 3463-3469
-
-
Saylors III, R.L.1
Stine, K.C.2
Sullivan, J.3
-
9
-
-
0028130504
-
Clinical pharmacodynamics of continuous infusion topotecan in children: Systemic exposure predicts hematologic toxicity
-
Stewart CF, Baker SD, Heideman RL, Jones D, Crom WR, Pratt CB. Clinical pharmacodynamics of continuous infusion topotecan in children: systemic exposure predicts hematologic toxicity. J Clin Oncol 1994;12:1946-54.
-
(1994)
J Clin Oncol
, vol.12
, pp. 1946-1954
-
-
Stewart, C.F.1
Baker, S.D.2
Heideman, R.L.3
Jones, D.4
Crom, W.R.5
Pratt, C.B.6
-
10
-
-
0032054147
-
Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts
-
Zamboni WC, Stewart CF, Thompson J, et al. Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts. J Natl Cancer Inst 1998;90:505-11.
-
(1998)
J Natl Cancer Inst
, vol.90
, pp. 505-511
-
-
Zamboni, W.C.1
Stewart, C.F.2
Thompson, J.3
-
11
-
-
10244270659
-
Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: A pediatric oncology group study
-
Tubergen DG, Stewart CF, Pratt CB, et al. Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: a pediatric oncology group study. J Pediatr Hematol Oncol 1996;18:352-61.
-
(1996)
J Pediatr Hematol Oncol
, vol.18
, pp. 352-361
-
-
Tubergen, D.G.1
Stewart, C.F.2
Pratt, C.B.3
-
12
-
-
23044452535
-
Improved response in high-risk neuroblastoma with protracted topotecan administration using a pharmacokinetically guided dosing approach
-
Santana VM, Furman WL, Billups CA, et al. Improved response in high-risk neuroblastoma with protracted topotecan administration using a pharmacokinetically guided dosing approach. J Clin Oncol 2005;23:4039-47.
-
(2005)
J Clin Oncol
, vol.23
, pp. 4039-4047
-
-
Santana, V.M.1
Furman, W.L.2
Billups, C.A.3
-
13
-
-
0032920492
-
Interpatient variability in bioavailability of the intravenous formulation of topotecan given orally to children with recurrent solid tumors
-
Zamboni WC, Bowman LC, Tan M, et al. Interpatient variability in bioavailability of the intravenous formulation of topotecan given orally to children with recurrent solid tumors. Cancer Chemother Pharmacol 1999;43:454-60.
-
(1999)
Cancer Chemother Pharmacol
, vol.43
, pp. 454-460
-
-
Zamboni, W.C.1
Bowman, L.C.2
Tan, M.3
-
14
-
-
36749093099
-
-
NONMEM Users' Guide Part I-VIII. San Francisco (CA): NONMEM Project Group, University of California at San Francisco; 1998.
-
NONMEM Users' Guide Part I-VIII. San Francisco (CA): NONMEM Project Group, University of California at San Francisco; 1998.
-
-
-
-
15
-
-
23744450342
-
Monte Carlo parametric expectation maximization (MC-PEM) method for analyzing population pharmacokinetic/pharmacodynamic data
-
D'Argenio DZ, editor, NewYork NY, Springer;
-
Bauer RJ, Guzy S. Monte Carlo parametric expectation maximization (MC-PEM) method for analyzing population pharmacokinetic/pharmacodynamic data. In: D'Argenio DZ, editor. Advanced methods of pharmacokinetics and pharmacodynamic systems analysis. NewYork (NY): Springer; 2004.
-
(2004)
Advanced methods of pharmacokinetics and pharmacodynamic systems analysis
-
-
Bauer, R.J.1
Guzy, S.2
-
16
-
-
18344394148
-
Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors
-
Mould DR, Holford NH, Schellens JH, et al. Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors. Clin Pharmacol Ther 2002;71:334-48.
-
(2002)
Clin Pharmacol Ther
, vol.71
, pp. 334-348
-
-
Mould, D.R.1
Holford, N.H.2
Schellens, J.H.3
-
17
-
-
0037764013
-
Glomerular filtration rate in children with solid tumors: Normative values and a new method for estimation
-
Brandt JR, Wong C, Jones DR, et al. Glomerular filtration rate in children with solid tumors: normative values and a new method for estimation. Pediatr Hematol Oncol 2003;20:309-18.
-
(2003)
Pediatr Hematol Oncol
, vol.20
, pp. 309-318
-
-
Brandt, J.R.1
Wong, C.2
Jones, D.R.3
-
18
-
-
33750335084
-
Population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in paediatric cystic fibrosis and bone marrow transplant patients
-
Hennig S, Wainwright CE, Bell SC, Miller H, Friberg LE, Charles BG. Population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in paediatric cystic fibrosis and bone marrow transplant patients. Clin Pharmacokinet 2006;45:1099-114.
-
(2006)
Clin Pharmacokinet
, vol.45
, pp. 1099-1114
-
-
Hennig, S.1
Wainwright, C.E.2
Bell, S.C.3
Miller, H.4
Friberg, L.E.5
Charles, B.G.6
-
19
-
-
81255204082
-
Nonlinear mixed effects models: Practical issues
-
Bonate PL, editor, New York NY, Springer Science-Business Media, Inc
-
Bonate P. Nonlinear mixed effects models: practical issues. In: Bonate PL, editor. Pharmacokinetic-pharmacodynamic modeling and simulation. New York (NY): Springer Science-Business Media, Inc.; 2006. p. 267-307.
-
(2006)
Pharmacokinetic-pharmacodynamic modeling and simulation
, pp. 267-307
-
-
Bonate, P.1
-
20
-
-
0019604592
-
Some suggestions for measuring predictive performance
-
Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981;9:503-12.
-
(1981)
J Pharmacokinet Biopharm
, vol.9
, pp. 503-512
-
-
Sheiner, L.B.1
Beal, S.L.2
-
21
-
-
0031924558
-
Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma
-
Zamboni WC, Gajjar AJ, Heideman RL, et al. Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma. Clin Cancer Res 1998;4:783-9.
-
(1998)
Clin Cancer Res
, vol.4
, pp. 783-789
-
-
Zamboni, W.C.1
Gajjar, A.J.2
Heideman, R.L.3
-
22
-
-
0034086522
-
Population pharmacokinetic model for topotecan derived from phase I clinical trials
-
Gallo JM, Laub PB, Rowinsky EK, Grochow LB, Baker SD. Population pharmacokinetic model for topotecan derived from phase I clinical trials. J Clin Oncol 2000;18:2459-67.
-
(2000)
J Clin Oncol
, vol.18
, pp. 2459-2467
-
-
Gallo, J.M.1
Laub, P.B.2
Rowinsky, E.K.3
Grochow, L.B.4
Baker, S.D.5
-
23
-
-
0033729430
-
Population pharmacokinetics of topotecan: Intraindividual variability in total drug
-
Montazeri A, Boucaud M, Lokiec F, et al. Population pharmacokinetics of topotecan: intraindividual variability in total drug. Cancer Chemother Pharmacol 2000;46:375-81.
-
(2000)
Cancer Chemother Pharmacol
, vol.46
, pp. 375-381
-
-
Montazeri, A.1
Boucaud, M.2
Lokiec, F.3
-
24
-
-
1342322765
-
Factors affecting pharmacokinetic variability of oral topotecan: A population analysis
-
Leger F, Loos WJ, Fourcade J, et al. Factors affecting pharmacokinetic variability of oral topotecan: a population analysis. Br J Cancer 2004;90:343-7.
-
(2004)
Br J Cancer
, vol.90
, pp. 343-347
-
-
Leger, F.1
Loos, W.J.2
Fourcade, J.3
-
25
-
-
0141889555
-
Modeling plasma and saliva topotecan concentration time course using a population approach
-
Boucaud M, Pinguet F, Culine S, et al. Modeling plasma and saliva topotecan concentration time course using a population approach. Oncol Res 2003;13:211-9.
-
(2003)
Oncol Res
, vol.13
, pp. 211-219
-
-
Boucaud, M.1
Pinguet, F.2
Culine, S.3
-
26
-
-
0029810681
-
Topoisomerase I interactive drugs in children with cancer
-
Stewart CF, Zamboni WC, Crom WR, et al. Topoisomerase I interactive drugs in children with cancer. Invest New Drugs 1996;14:37-47.
-
(1996)
Invest New Drugs
, vol.14
, pp. 37-47
-
-
Stewart, C.F.1
Zamboni, W.C.2
Crom, W.R.3
-
28
-
-
15444358162
-
Probenecid alters topotecan systemic and renal disposition by inhibiting tubular secretion
-
Zamboni WC, Houghton PJ, Johnson RK, et al. Probenecid alters topotecan systemic and renal disposition by inhibiting tubular secretion. J Pharmacol Exp Ther 1998;284:89-94.
-
(1998)
J Pharmacol Exp Ther
, vol.284
, pp. 89-94
-
-
Zamboni, W.C.1
Houghton, P.J.2
Johnson, R.K.3
|